文献速递临床试验与 GCP基础与转化研究

AIPL1相关严重视网膜营养不良儿童的基因治疗:一项开放标签、首次人体干预研究

Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.
PubMed 文献 · Lancet · 2025-01-01

这项在英国开展的开放标签、首次人体干预研究,纳入4名年龄1.0至2.8岁、携带AIPL1双等位基因致病序列变异的严重视网膜营养不良儿童,通过视网膜下注射rAAV8.hRKp.AIPL1并口服泼尼松龙。干预后平均3.5年,治疗眼视力从基线2.7 logMAR改善至平均0.9 logMAR,未治疗眼视力至最终随访不可测;部分患儿视觉功能、视觉诱发电位及视网膜结构保留优于未治疗眼,1例治疗眼出现囊样黄斑水肿,无其他安全性问题。

要点

  • 4名AIPL1相关严重视网膜营养不良儿童接受视网膜下rAAV8.hRKp.AIPL1注射,并口服泼尼松龙预防炎症。
  • 干预后平均3.5年,治疗眼视力从基线2.7 logMAR改善至平均0.9 logMAR,未治疗眼视力不可测。
  • 1例治疗眼发生囊样黄斑水肿,未发现其他安全性问题。

核心结论

  • 研究结果表明,年幼的AIPL1相关视网膜营养不良儿童从视网膜下注射rAAV8.hRKp.AIPL1中显著获益,视力和功能性视觉改善,并有证据表明对进行性视网膜变性有一定保护作用,且无严重不良事件。

研究设计与样本

  • 非随机、单臂临床研究,在英国开展,纳入4名年龄1.0至2.8岁、携带AIPL1双等位基因致病序列变异的严重视网膜营养不良儿童。
  • 研究产品为重组腺相关病毒载体rAAV8.hRKp.AIPL1,由人视紫红质激酶启动子区驱动人AIPL1编码序列,根据英国药品和健康产品管理局(MHRA)的特殊许可生产,并在当地伦理批准下提供给患病儿童。
  • 每名儿童一只眼接受视网膜下注射,并口服泼尼松龙以预防炎症损害。
  • 结局指标包括视力(采用新型触摸屏测试评估)、功能性视觉(通过观察和记录儿童视觉行为及完成简单视觉引导任务的能力评估)、视觉诱发电位(通过记录全屏黑白闪烁刺激的皮层电生理反应评估)和视网膜结构(采用手持光学相干断层扫描[OCT]和广角眼底成像评估)。
  • 通过裂隙灯生物显微镜检查和散瞳眼底镜检查识别不良事件(包括炎症和视网膜脱离);安全性还通过视力测试、眼底镜检查、手持OCT和广角眼底成像评估。

主要发现

  • 患者于2019年7月12日至2020年3月16日期间被选择接受治疗;干预前,患儿双眼视力限于光感。
  • 干预后平均3.5年(范围3.0至4.1年),治疗眼视力改善至平均0.9 logMAR(范围0.8至1.0),干预前视力相当于2.7 logMAR。
  • 未治疗眼视力在最终随访时变为不可测。
  • 在能够配合测试的2名儿童中,客观视力测试证实视觉功能改善,视觉诱发电位测量显示视觉皮层活动增强,且为治疗眼特异性。
  • 3名儿童治疗眼的外层视网膜结构分层保留优于未治疗眼;所有4名儿童治疗眼的视网膜厚度保留均优于未治疗眼。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retinal dystrophy caused by genetic deficiency of AIPL1 causes severe and rapidly progressive impairment of sight from birth. We sought to evaluate whether early intervention by gene supplementation therapy was safe and could improve outcomes in children with this condition. METHODS: This non-randomised, single-arm, clinical study conducted in the UK involved four children aged 1·0-2·8 years with severe retinal dystrophy associated with biallelic disease-causing sequence variants in AIPL1. We designed a recombinant adeno-associated viral vector comprising the human AIPL1 coding sequence driven by a human rhodopsin kinase promoter region (rAAV8.hRKp.AIPL1). The product was manufactured under a Specials Licence from the Medicines and Health products Regulatory Authority (UK) and made available to affected children with local ethics approval. We administered the product to one eye of each child by subretinal injection. The children were prescribed oral prednisolone to protect against harm from inflammation. Outcome measures included visual acuity (as assessed with a novel touchscreen test), functional vision (assessed by observing and recording the children's visual behaviour and their ability to perform simple vision-guided tasks), visual evoked potentials (assessed by recording cortical electrophysiological responses to full-screen black-and-white flickering stimuli), and retinal structure (assessed with handheld optical coherence tomography [OCT] and widefield fundus imaging). To identify adverse effects, including inflammation and retinal detachment, we conducted ocular examinations using slit-lamp biomicroscopy and dilated fundoscopy. Safety was further assessed by testing of visual acuity, ophthalmoscopy, handheld OCT and widefield fundus imaging. FINDINGS: Patients were selected for treatment between July 12, 2019, and March 16, 2020. Before intervention, the children's binocular visual acuities were limited to perception of light. At a mean of 3·5 years (range 3·0-4·1) after intervention, the visual acuities of the children's treated eyes had improved to a mean of 0·9 logarithm of the minimal angle of the minimum angle of resolution ([logMAR] range 0·8-1·0); visual acuities before intervention were equivalent to 2·7 logMAR. In contrast, the visual acuities of the children's untreated eyes became unmeasurable at the final follow-up. In the two children able to comply with testing, an objective test of visual acuity confirmed improvements in visual function, and measurement of visual evoked potentials showed enhanced activity of the visual cortex, specific to the treated eyes. In three of the children, structural lamination of the outer retina was better preserved in the treated eye than in the untreated eye, and, for all four children, retinal thickness appeared better preserved in the treated eye than in the untreated eye. The treated eye of one child developed cystoid macular oedema. No other safety concerns were identified. INTERPRETATION: Our findings indicate that young children with AIPL1-related retinal dystrophy benefited substantially from subretinal administration of rAAV8.hRKp.AIPL1, with improved visual acuity and functional vision and evidence of some protection against progressive retinal degeneration, without serious adverse effects. FUNDING: UK National Institute for Health Research and Moorfields Eye Charity.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Michaelides M, Laich Y, Wong SC, et al. Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study. Lancet. 2025. PMID: 39986747. doi:10.1016/S0140-6736(24)02812-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。